Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colonic Neoplasms 2Vaso-Occlusive Crises 1Seaweed Associated Changes in Healthy Subjects 1Prostatic Neoplasms 1Proctitis 1Polycystic Ovary Syndrome 1Neoplasms 1Insulin Resistance 1Hyperandrogenism 1Head and Neck Neoplasms 1Glucose Intolerance 1Diarrhea 1Colorectal Neoplasms 1Colonic Polyps 1Anovulation 1Anemia, Sickle Cell 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × maltodextrin × Clear all
NCT02819960 2022-12-14

Prevention of Irinotecan Induced Diarrhea by Probiotics

S&D Pharma SK s.r.o.

Phase 3 Completed
233 enrolled

Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡